Overview

A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy

Status:
Completed

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients with type 2 diabetes mellitus who are currently on metformin monotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

ConjuChem

Treatments:

Metformin